{"title":"在越南购买碳青霉烯类药物,这是一个低至中等收入的药品市场,抗菌素耐药性负担很高。","authors":"Ninh Thi Nhu Quynh, Vu Quoc Dat","doi":"10.4103/WHO-SEAJPH.WHO-SEAJPH_76_21","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Carbapenems are the last-resort antibiotics used for the treatment of multidrug-resistant bacterial infections. We reported the expenditure and prices of carbapenems in public healthcare institutions in Vietnam.</p><p><strong>Materials and methods: </strong>Data on carbapenem procurement were obtained from tender-winning bids from provincial health authorities and public hospitals from 2013 to 2018. We use the anatomical therapeutic chemical index 2019 and the defined daily doses (DDDs) to describe the purchase (in number of DDD) and the price of carbapenem (presented in US dollar per DDD).</p><p><strong>Results: </strong>There are four available carbapenems in Vietnam between 2013 and 2018. Imipenem/cilastatin was the most common purchased antibiotic, accounting for 50.7% of total carbapenem consumption. The vast majority of carbapenem purchase (in DDD) was imported (79.1%). By 2018, among available carbapenems, the average price of doripenem was the highest (US $85.25/DDD), followed by meropenem (US $39.4/DDD), imipenem/cilastatin (US $36.5/DDD), and ertapenem (US $24.5 per DDD). The average carbapenem price decreased by 6.3% annually. The price of doripenem (P = -0.8518, r = 0.0313) and meropenem (P = 0.8875, r = 0.0183) had a significant correlation with the number of manufacturers in the market. The price variability and the number of manufacturers of doripenem (P = 0.8173, r = 0.047) and meropenem (P = -0.8116, r = 0.499) also had a strong positive correlation.</p><p><strong>Conclusion: </strong>The price of carbapenems in the Vietnam pharmaceutical market was high. Monitoring the price and consumption of last-resort antibiotic are needed to ensure availability of antibiotics in the setting with high burden of antibiotic drug resistance.</p>","PeriodicalId":37393,"journal":{"name":"WHO South-East Asia journal of public health","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Purchase of carbapenems in Vietnam, a low- to middle-income pharmaceutical market with a high burden of antimicrobial drug resistance.\",\"authors\":\"Ninh Thi Nhu Quynh, Vu Quoc Dat\",\"doi\":\"10.4103/WHO-SEAJPH.WHO-SEAJPH_76_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Carbapenems are the last-resort antibiotics used for the treatment of multidrug-resistant bacterial infections. We reported the expenditure and prices of carbapenems in public healthcare institutions in Vietnam.</p><p><strong>Materials and methods: </strong>Data on carbapenem procurement were obtained from tender-winning bids from provincial health authorities and public hospitals from 2013 to 2018. We use the anatomical therapeutic chemical index 2019 and the defined daily doses (DDDs) to describe the purchase (in number of DDD) and the price of carbapenem (presented in US dollar per DDD).</p><p><strong>Results: </strong>There are four available carbapenems in Vietnam between 2013 and 2018. Imipenem/cilastatin was the most common purchased antibiotic, accounting for 50.7% of total carbapenem consumption. The vast majority of carbapenem purchase (in DDD) was imported (79.1%). By 2018, among available carbapenems, the average price of doripenem was the highest (US $85.25/DDD), followed by meropenem (US $39.4/DDD), imipenem/cilastatin (US $36.5/DDD), and ertapenem (US $24.5 per DDD). The average carbapenem price decreased by 6.3% annually. The price of doripenem (P = -0.8518, r = 0.0313) and meropenem (P = 0.8875, r = 0.0183) had a significant correlation with the number of manufacturers in the market. The price variability and the number of manufacturers of doripenem (P = 0.8173, r = 0.047) and meropenem (P = -0.8116, r = 0.499) also had a strong positive correlation.</p><p><strong>Conclusion: </strong>The price of carbapenems in the Vietnam pharmaceutical market was high. Monitoring the price and consumption of last-resort antibiotic are needed to ensure availability of antibiotics in the setting with high burden of antibiotic drug resistance.</p>\",\"PeriodicalId\":37393,\"journal\":{\"name\":\"WHO South-East Asia journal of public health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"WHO South-East Asia journal of public health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/WHO-SEAJPH.WHO-SEAJPH_76_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"WHO South-East Asia journal of public health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/WHO-SEAJPH.WHO-SEAJPH_76_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
碳青霉烯类是治疗多重耐药细菌感染的最后手段。我们报告了越南公共卫生机构碳青霉烯类药物的支出和价格。材料与方法:收集2013 - 2018年各省级卫生主管部门和公立医院招标采购碳青霉烯类的数据。我们使用解剖治疗化学指数2019和定义日剂量(DDDs)来描述碳青霉烯的购买(DDD数量)和价格(以美元/ DDD表示)。结果:2013 - 2018年越南有4种可用的碳青霉烯类药物。亚胺培南/西司他汀是最常见的抗生素,占碳青霉烯类抗生素总消费量的50.7%。绝大多数碳青霉烯采购(DDD)为进口(79.1%)。到2018年,在可获得的碳青霉烯类药物中,多利培南的平均价格最高(85.25美元/DDD),其次是美罗培南(39.4美元/DDD)、亚胺培南/西司他汀(36.5美元/DDD)和厄他培南(24.5美元/DDD)。碳青霉烯平均价格每年下降6.3%。多利培南(P = -0.8518, r = 0.0313)和美罗培南(P = 0.8875, r = 0.0183)的价格与市场上的生产企业数量有显著相关。多利培南(P = 0.8173, r = 0.047)和美罗培南(P = -0.8116, r = 0.499)的价格变异性与生产企业数量也有较强的正相关。结论:越南医药市场碳青霉烯类药品价格偏高。需要监测最后手段抗生素的价格和消费,以确保在抗生素耐药负担高的环境中获得抗生素。
Purchase of carbapenems in Vietnam, a low- to middle-income pharmaceutical market with a high burden of antimicrobial drug resistance.
Introduction: Carbapenems are the last-resort antibiotics used for the treatment of multidrug-resistant bacterial infections. We reported the expenditure and prices of carbapenems in public healthcare institutions in Vietnam.
Materials and methods: Data on carbapenem procurement were obtained from tender-winning bids from provincial health authorities and public hospitals from 2013 to 2018. We use the anatomical therapeutic chemical index 2019 and the defined daily doses (DDDs) to describe the purchase (in number of DDD) and the price of carbapenem (presented in US dollar per DDD).
Results: There are four available carbapenems in Vietnam between 2013 and 2018. Imipenem/cilastatin was the most common purchased antibiotic, accounting for 50.7% of total carbapenem consumption. The vast majority of carbapenem purchase (in DDD) was imported (79.1%). By 2018, among available carbapenems, the average price of doripenem was the highest (US $85.25/DDD), followed by meropenem (US $39.4/DDD), imipenem/cilastatin (US $36.5/DDD), and ertapenem (US $24.5 per DDD). The average carbapenem price decreased by 6.3% annually. The price of doripenem (P = -0.8518, r = 0.0313) and meropenem (P = 0.8875, r = 0.0183) had a significant correlation with the number of manufacturers in the market. The price variability and the number of manufacturers of doripenem (P = 0.8173, r = 0.047) and meropenem (P = -0.8116, r = 0.499) also had a strong positive correlation.
Conclusion: The price of carbapenems in the Vietnam pharmaceutical market was high. Monitoring the price and consumption of last-resort antibiotic are needed to ensure availability of antibiotics in the setting with high burden of antibiotic drug resistance.
期刊介绍:
The journal will cover technical and clinical studies related to health, ethical and social issues in field of Public Health, Epidemiology, primary health care, epidemiology, health administration, health systems, health economics, health promotion, public health nutrition, communicable and non-communicable diseases, maternal and child health, occupational and environmental health, social and preventive medicine. Articles with clinical interest and implications will be given preference.